Denali Therapeutics (DNLI) 10-Q2023 Q1 Quarterly report

Filed: 8 May 23, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAN, Academy, adaptive, Amyloid, auditory, bank, Becerra, behavior, Beta, Biotechnologische, brainstem, Catalyst, Cir, circuit, clarify, cognitive, dermatan, easily, exploratory, FDORA, flexibility, flipping, foot, forgo, framework, Franc, HEALEY, hearing, IRA, ISR, leasehold, longstanding, myasthenic, OTV, President, sector, Shareholder, speed, twelve, tying, unavailability, unavailable, urine, WORLDSymposiumTM

Removed: addressed, Alexander, allege, annually, approvability, assist, attempting, automatic, Bio, bioresearch, boxed, bribe, cancer, chosen, CNS, Committee, communication, complicating, conceal, concealing, constitutionality, contingency, continual, covertly, custody, decided, deferred, defraud, detain, device, dismissing, divergent, durable, Elimination, emerged, evidenced, falsifying, family, frequent, globally, guide, headache, HIMALAYA, impacted, implanted, implementing, individually, infection, informal, infused, inhaled, injected, innovative, Inspector, instilled, interactive, intermediate, Japan, join, jointly, kickback, kind, knowingly, landlord, learned, locally, medication, MHRA, misappropriate, mutation, mutually, nausea, nonrenewal, noted, nurse, obligated, open, outlining, overtly, owe, packaging, payer, penalty, preempted, presenting, prioritized, qui, rating, reach, recommendation, recommending, referral, reimbursed, released, remote, remuneration, replenishment, representing, resolve, responsibility, resume, resumed, rigorously, role, routine, ruling, SAE, safest, sampling, scheme, Schuth, seize, sequester, showing, soliciting, space, specialty, standing, Steve, stopped, subjected, superiority, surveillance, sustainability, tam, tasked, Tau, Taxpayer, teaching, telecommute, tracking, tradeable, transmission, trick, trillion, unconstrained, unspecified, utilization, vaccination, vast, violate, voluntary, whistleblower, willfully, WORLDSymposium, worsen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

DNLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, Alexander O. Schuth, M.D., Chief Operating and Financial Officer of Denali Therapeutics Inc. (the “Company”), hereby certify that:

1.The Company’s Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2023, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2023


By:			/s/ Alexander O. Schuth
Name:			Alexander O. Schuth, M.D.
Title:			Chief Operating and Financial Officer